Table 3 Baseline characteristics of the study participants at commencement of HAART, total and gender segregated
Characteristic | Total | Female | Male | p-value* |
|---|---|---|---|---|
(N = 1741) | (N = 1413) | (N = 328) | ||
Age in years, median (IQR) | 44(37,50) | 43(37,49) | 45(40,52) | 0.001 |
WHO stage III & IV, n (%) | 1113(63.9) | 929(65.7) | 184(56.1) | 0.121 |
CD4 cells/μ l, median (IQR) (2005–6) | 128(55,190) | 144(65,191) | 49(49,92) | 0.074 |
ART regime (2005–2013), n (%) | ||||
d4T + 3TC+ NVP | 693(40) | 638(45) | 136(41) | 0.233 |
ZDV +3TC + NPV | 774(44) | 562(40) | 131(40) | |
Other ** | 274(16) | 213(15) | 61(19) |